Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56,078,244
-
Total 13F shares
-
38,616,493
-
Share change
-
-2,038,377
-
Total reported value
-
$95,766,554
-
Price per share
-
$2.48
-
Number of holders
-
92
-
Value change
-
-$4,378,950
-
Number of buys
-
63
-
Number of sells
-
42
Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q2 2025
As of 30 Jun 2025,
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by
92 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
38,616,493 shares.
The largest 10 holders included
T. Rowe Price Investment Management, Inc., Vestal Point Capital, LP, NEA Management Company, LLC, Bellevue Group AG, VANGUARD GROUP INC, TANG CAPITAL MANAGEMENT LLC, BlackRock, Inc., Siren, L.L.C., MILLENNIUM MANAGEMENT LLC, and MARSHALL WACE, LLP.
This page lists
92
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.